Parametric Portfolio Associates’s Sarepta Therapeutics SRPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q1 | $6.97M | Sell |
89,197
-75,199
| -46% | -$5.76M | ﹤0.01% | 1625 |
|
|
2021
Q4 | $14.8M | Sell |
164,396
-4,717
| -3% | -$403K | 0.01% | 1137 |
|
|
2021
Q3 | $15.6M | Sell |
169,113
-5,861
| -3% | -$451K | 0.01% | 1057 |
|
|
2021
Q2 | $13.6M | Buy |
174,974
+64,464
| +58% | +$4.89M | 0.01% | 1170 |
|
|
2021
Q1 | $8.24M | Sell |
110,510
-16,446
| -13% | -$1.52M | ﹤0.01% | 1813 |
|
|
2020
Q4 | $21.6M | Buy |
126,956
+9,631
| +8% | +$1.43M | 0.01% | 996 |
|
|
2020
Q3 | $16.5M | Buy |
117,325
+537
| +0.5% | +$81.6K | 0.01% | 1024 |
|
|
2020
Q2 | $18.7M | Sell |
116,788
-43,505
| -27% | -$5.92M | 0.01% | 920 |
|
|
2020
Q1 | $15.7M | Buy |
160,293
+16,911
| +12% | +$1.93M | 0.01% | 934 |
|
|
2019
Q4 | $18.5M | Buy |
143,382
+23,054
| +19% | +$2.33M | 0.01% | 1035 |
|
|
2019
Q3 | $9.06M | Sell |
120,328
-16,037
| -12% | -$1.89M | 0.01% | 1528 |
|
|
2019
Q2 | $20.7M | Buy |
136,365
+5,883
| +5% | +$715K | 0.02% | 910 |
|
|
2019
Q1 | $15.6M | Buy |
130,482
+8,709
| +7% | +$1.12M | 0.01% | 1083 |
|
|
2018
Q4 | $13.3M | Sell |
121,773
-9,388
| -7% | -$1.17M | 0.01% | 1099 |
|
|
2018
Q3 | $21.2M | Buy |
131,161
+2,580
| +2% | +$353K | 0.02% | 863 |
|
|
2018
Q2 | $17M | Sell |
128,581
-262
| -0.2% | -$24.7K | 0.02% | 950 |
|
|
2018
Q1 | $9.55M | Sell |
128,843
-23,543
| -15% | -$1.57M | 0.01% | 1369 |
|
|
2017
Q4 | $8.48M | Buy |
152,386
+16,288
| +12% | +$863K | 0.01% | 1455 |
|
|
2017
Q3 | $6.17M | Buy |
136,098
+26,280
| +24% | +$1.05M | 0.01% | 1666 |
|
|
2017
Q2 | $3.7M | Buy |
109,818
+784
| +0.7% | +$25.5K | ﹤0.01% | 2042 |
|
|
2017
Q1 | $3.23M | Buy |
109,034
+4,785
| +5% | +$148K | ﹤0.01% | 2114 |
|
|
2016
Q4 | $2.86M | Sell |
104,249
-43,908
| -30% | -$1.76M | ﹤0.01% | 2125 |
|
|
2016
Q3 | $9.1M | Buy |
148,157
+11,884
| +9% | +$359K | 0.01% | 1042 |
|
|
2016
Q2 | $2.6M | Buy |
136,273
+110,619
| +431% | +$2.05M | ﹤0.01% | 2125 |
|
|
2016
Q1 | $501K | Buy |
25,654
+18,633
| +265% | +$326K | ﹤0.01% | 3325 |
|
|
2015
Q4 | $271K | Sell |
7,021
-7,058
| -50% | -$229K | ﹤0.01% | 3600 |
|
|
2015
Q3 | $452K | Buy |
14,079
+6,497
| +86% | +$220K | ﹤0.01% | 2772 |
|
|
2015
Q2 | $231K | Buy |
+7,582
| New | +$155K | ﹤0.01% | 3702 |
|
|
2015
Q1 | – | Sell |
-15,334
| Closed | -$222K | – | 3997 |
|
|
2014
Q4 | $222K | Buy |
+15,334
| New | +$260K | ﹤0.01% | 3728 |
|
|
2014
Q3 | – | Sell |
-12,013
| Closed | -$358K | – | 3859 |
|
|
2014
Q2 | $358K | Buy |
+12,013
| New | +$380K | ﹤0.01% | 3418 |
|
|
2013
Q4 | – | Sell |
-5,823
| Closed | -$275K | – | 3843 |
|
|
2013
Q3 | $275K | Buy |
+5,823
| New | +$224K | ﹤0.01% | 3440 |
|
Other funds holding SRPT
ACA
EC
Parametric Portfolio Associates's SRPT Position: Q1 2022 in Review
Parametric Portfolio Associates reduced its Sarepta Therapeutics (SRPT) stake by 46% in Q1 2022, selling an estimated $5.76M and leaving 89,197 shares worth $6.97M. The position accounts for ﹤0.01% of the portfolio, ranked #1625.
Parametric Portfolio Associates first reported a position in SRPT in Q3 2013 and has held it in 31 quarters since. The position peaked at $21.6M in Q4 2020. 328 funds tracked by Wall St. Rank hold SRPT as of Q1 2022.
- Parametric Portfolio Associates held 89,197 shares of Sarepta Therapeutics worth $6.97M as of Q1 2022.
- Parametric Portfolio Associates sold 75,199 Sarepta Therapeutics shares in Q1 2022, an estimated $5.76M.
- Sarepta Therapeutics made up ﹤0.01% of Parametric Portfolio Associates's portfolio in Q1 2022, its #1625 holding.
- Parametric Portfolio Associates first reported a position in Sarepta Therapeutics in Q3 2013 and has held it in 31 quarters since.
- Parametric Portfolio Associates's Sarepta Therapeutics position peaked at $21.6M in Q4 2020.
- 328 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2022.
Based on Parametric Portfolio Associates's 13F filing for Q1 2022, filed 16 May 2022.